News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,010 Results
Type
Article (13761)
Company Profile (101)
Press Release (251148)
Section
Business (88039)
Career Advice (465)
Deals (15343)
Drug Delivery (67)
Drug Development (36599)
Employer Resources (49)
FDA (6288)
Job Trends (6197)
News (150202)
Policy (14027)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (440)
Adcomms (6)
Allergies (32)
Alliances (23211)
ALS (36)
Alzheimer's disease (384)
Antibody-drug conjugate (ADC) (35)
Approvals (6323)
Artificial intelligence (100)
Autoimmune disease (7)
Automation (3)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (54)
Biotechnology (40)
Bladder cancer (18)
Brain cancer (15)
Breast cancer (74)
Cancer (569)
Cardiovascular disease (67)
Career advice (407)
Career pathing (11)
CAR-T (20)
Cell therapy (81)
Cervical cancer (4)
Clinical research (30843)
Collaboration (319)
Compensation (131)
Complete response letters (16)
COVID-19 (759)
CRISPR (19)
C-suite (112)
Cystic fibrosis (35)
Data (576)
Denatured (15)
Depression (9)
Diabetes (75)
Diagnostics (1316)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (54)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32041)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37367)
Executive appointments (346)
FDA (6669)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (202)
Gene editing (37)
Generative AI (8)
Gene therapy (97)
GLP-1 (336)
Government (1286)
Grass and pollen (2)
Guidances (15)
Healthcare (3562)
Huntington's disease (4)
IgA nephropathy (9)
Immunology and inflammation (33)
Indications (12)
Infectious disease (790)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (43)
Interviews (59)
IPO (5874)
IRA (29)
Job creations (2051)
Job search strategy (373)
Kidney cancer (6)
Labor market (10)
Layoffs (177)
Leadership (3)
Legal (3429)
Liver cancer (19)
Lung cancer (75)
Lymphoma (50)
Machine learning (1)
Management (16)
Manufacturing (140)
MASH (30)
Medical device (1273)
Medtech (1275)
Mergers & acquisitions (9653)
Metabolic disorders (243)
Multiple sclerosis (17)
NASH (14)
Neurodegenerative disease (21)
Neuropsychiatric disorders (6)
Neuroscience (544)
NextGen: Class of 2025 (1586)
Non-profit (593)
Northern California (663)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (21)
Pain (49)
Pancreatic cancer (13)
Parkinson's disease (41)
Partnered (5)
Patents (102)
Patient recruitment (28)
Peanut (10)
People (28848)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8027)
Phase II (13048)
Phase III (11710)
Pipeline (376)
Podcasts (46)
Policy (58)
Postmarket research (1401)
Preclinical (3206)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (119)
Rare diseases (156)
Real estate (2634)
Recruiting (17)
Regulatory (10073)
Reports (14)
Research institute (563)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (1)
RSV (6)
Schizophrenia (32)
Series A (35)
Series B (11)
Service/supplier (3)
Sickle cell disease (30)
Southern California (678)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1628)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (28)
United States (6727)
Vaccines (149)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Last 7 days (189)
Last 30 days (854)
Last 365 days (12040)
2025 (2859)
2024 (12501)
2023 (14246)
2022 (19556)
2021 (20072)
2020 (19034)
2019 (14886)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11396)
2011 (11923)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (53)
Arkansas (3)
Asia (20079)
Australia (2602)
California (1606)
Canada (863)
China (224)
Colorado (65)
Connecticut (65)
Delaware (51)
Europe (39331)
Florida (299)
Georgia (35)
Idaho (9)
Illinois (180)
India (14)
Indiana (127)
Iowa (1)
Japan (83)
Kansas (55)
Kentucky (12)
Maine (2)
Maryland (245)
Massachusetts (1380)
Michigan (27)
Minnesota (89)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (699)
New Mexico (7)
New York (466)
North Carolina (374)
North Dakota (2)
Northern California (663)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (405)
Puerto Rico (8)
Rhode Island (7)
South America (501)
South Carolina (2)
Southern California (678)
Tennessee (34)
Texas (215)
Utah (33)
Virginia (69)
Washington D.C. (29)
Washington State (109)
Wisconsin (14)
265,010 Results for "glenmark pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1%
February 13, 2025
·
1 min read
Press Releases
Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL)
February 14, 2025
·
2 min read
Press Releases
Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
March 21, 2025
·
2 min read
Press Releases
Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials
March 4, 2025
·
2 min read
Press Releases
Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial
February 27, 2025
·
2 min read
Press Releases
Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC)
March 10, 2025
·
2 min read
Press Releases
Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules
January 22, 2025
·
2 min read
Pharm Country
Glenmark Pharmaceuticals Inc., USA Issues Voluntary Nationwide Recall for Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K Due To Failed Dissolution
Glenmark Pharmaceuticals Inc. is voluntarily recalling 114 batches of Potassium Chloride Extended-Release Capsules, USP 10 mEq K, to the consumer level.
June 25, 2024
·
13 min read
Business
Ichnos and Glenmark take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance - ‘Ichnos Glenmark Innovation’
Ichnos Sciences Inc. (Ichnos), a global, fully integrated, clinical-stage biotech company and Glenmark Pharmaceuticals Ltd. (Glenmark), a leading, research-driven, global pharmaceutical company, today announced the launch of their alliance – Ichnos Glenmark Innovation – to accelerate new drug discovery in cancer treatment.
January 30, 2024
·
4 min read
Pharm Country
Ichnos Glenmark Innovation Presents Preclinical Data for its Oncology Asset ISB 2001 at AACR 2024 Annual Meeting
Ichnos Glenmark Innovation (IGI), an alliance between Ichnos Sciences Inc., a global fully-integrated clinical-stage biotech company developing multispecifics™ in oncology, and Glenmark Pharmaceuticals Ltd., shared preclinical data for its oncology asset ISB 2001 during the oral presentation at the annual American Association for Cancer Research (AACR) 2024.
April 8, 2024
·
5 min read
1 of 26,501
Next
